Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I/IIa Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Single Ascending Doses and Multiple Doses of AHB-137 in Healthy Participants and HBeAg-negative CHB Patients Receiving Stable Nucleos(t)Ide Analogues (NAs) Treatment

Next Previous
Trial Profile

A Phase I/IIa Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Single Ascending Doses and Multiple Doses of AHB-137 in Healthy Participants and HBeAg-negative CHB Patients Receiving Stable Nucleos(t)Ide Analogues (NAs) Treatment

Status: Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 24 Dec 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs AHB 137 (Primary)
  • Indications Hepatitis B
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors AusperBio

Most Recent Events

  • 12 Dec 2025 According to an AusperBio media release, company announced full end-of-follow-up (EOF) data from this study were presented in an oral session at HEP-DART 2025 conference (December 7-11, Honolulu, USA).
  • 12 Dec 2025 Results presented in the AusperBio Media Release.
  • 21 Jul 2025 According to an AusperBio media release, In Mar 2025, key data from this phase IIa study were featured in a late-breaker oral presentation at the Asia-Pacific Association for the Study of the Liver (APASL) conference.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top